# Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.

> **NCT05097911** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 33 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** MTL-CEBPA
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05097911
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-02
- **Primary completion:** 2026-04
- **Final completion:** 2027-04
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05097911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05097911, "Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05097911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*